What does Sichuan Kelun-Biotech Biopharmaceutical do?

Kelun-Biotech discovers, develops, makes and sells new medicines, mainly for cancer, as well as for immune and metabolic diseases. Its main focus is antibody-drug conjugates (ADCs), which use an antibody to carry a potent drug straight to tumor cells. It works in China and internationally, and partners with global drugmakers such as Merck (MSD).

Healthcare · Biotechnology · 6990.HK

What Sichuan Kelun-Biotech Biopharmaceutical Does & How It Makes Money (6990.HK)

Updated October 2026 · reflects Sichuan Kelun-Biotech Biopharmaceutical's latest reported financials

Chinese biotech developing antibody-drug conjugates and other novel cancer drugs. It earns money by selling its approved drugs and through license and collaboration deals with partners such as Merck Sharp & Dohme, which can bring upfront, milestone and royalty-type payments.

Sichuan Kelun-Biotech Biopharmaceutical's story, moat and numbers — in a 3-minute visual book.

Explore Sichuan Kelun-Biotech Biopharmaceutical on TacticScale →

How Sichuan Kelun-Biotech Biopharmaceutical makes money

It earns money by selling its approved drugs and through license and collaboration deals with partners such as Merck Sharp & Dohme, which can bring upfront, milestone and royalty-type payments.

What Sichuan Kelun-Biotech Biopharmaceutical does

Sichuan Kelun-Biotech, incorporated in 2016 and headquartered in Chengdu, is a biopharmaceutical subsidiary of Sichuan Kelun Pharmaceutical. It develops, manufactures and commercializes novel drugs across oncology, immunology and metabolism, and is built mainly around antibody-drug conjugates (ADCs). Its lead asset, Sac-TMT, is a TROP2 ADC for advanced solid tumors, used alone or in combination. Trastuzumab botidotin targets HER2+ tumors. The pipeline also includes ADCs against CLDN18.2, Nectin-4 and other targets, a bispecific ADC (SKB571/MK-2750), a radioligand drug for bone metastases (SKB107), the PD-L1 antibody tagitanlimab, the EGFR antibody Cetuximab N01, and small molecules A400 (RET inhibitor) and A296 (STING agonist). Several assets carry MSD codes, which reflects its licensing ties with Merck Sharp & Dohme. It also has deals with Harbour BioMed, Windward Bio, Ellipses Pharma and Crescent Biopharma.

Products & services

Sac-TMT (TROP2 ADC)
Trastuzumab botidotin (HER2 ADC)
Tagitanlimab (PD-L1 antibody)
Cetuximab N01 (EGFR antibody)
SKB315 (CLDN18.2 ADC)
SKB410/MK-3120 (Nectin-4 ADC)

What is Sichuan Kelun-Biotech Biopharmaceutical worth?

Fair value: not published

A reliable owner-earnings fair value isn't available for this company yet — we'd rather say so than print a number we don't trust.

We show a fair value only when the method is trustworthy. See Sichuan Kelun-Biotech Biopharmaceutical on TacticScale →

Sector Healthcare Industry Biotechnology HQ China Ticker 6990.HK Official site

Related companies

Sichuan Kelun Pharmaceutical (002422.SZ) · Xencor (XNCR)

Understand Sichuan Kelun-Biotech Biopharmaceutical in 3 minutes →